NeuroPace (NPCE) EBITDA (2020 - 2026)

NeuroPace's EBITDA history runs 7 years deep, the most recent figure standing at -$5.6 million for Q1 2026.

• In Q1 2026, EBITDA fell 8.18% year-over-year to -$5.6 million; the TTM figure through Mar 2026 stood at -$16.8 million (up 18.48% YoY), while the FY2025 annual figure was -$16.3 million, up 24.61% from the prior year.
• EBITDA was -$5.6 million for Q1 2026 at NeuroPace, down from -$1.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.8 million in Q4 2025 to a low of -$13.2 million in Q2 2022.
• Historically, EBITDA has averaged -$7.5 million across 5 years, with a median of -$7.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA plunged 54.52% in 2022, then jumped 51.63% in 2025.
• A 5-year view of EBITDA shows it stood at -$10.9 million in 2022, then jumped by 43.22% to -$6.2 million in 2023, then jumped by 41.08% to -$3.7 million in 2024, then surged by 51.63% to -$1.8 million in 2025, then tumbled by 215.11% to -$5.6 million in 2026.
• The last three EBITDA figures came in at -$5.6 million (Q1 2026), -$1.8 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.